In terms of breast cancer tumor subtype, 9 patients (40.9%) had HR-positive/HER2-negative tumors, 5 (22.7%) had HR-positive/HER2-positive tumors, 1 (4.5%) had HR-negative/HER2-positive tumor, and 3 (13.6%) had triple negative tumors. This evidence concerns the gene ERBB2 and neoplasm.